Niagen Bioscience, Inc.
- NAGE ยท Nasdaq
- Medicinal Chemicals & Botanical Products
- Los Angeles, CA
- 117 employees
- CIK 0001386570
Updated from SEC filings through
Top things to know
Executives
- Rob Fried Chief Executive Officer 8-K, 2026-11-04
-
Robert N. Fried Chief Executive Officer 4, 2026-07-08 - Ozan Pamir Chief Financial Officer 4, 2026-07-08
- Carlos Luis Lopez SVP, General Counsel 4, 2026-07-08
-
Frank Jaksch Jr. Chairman of the Board and Director 10-K, 2026-03-04
What leadership is saying
“During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
Niagen Bioscience, Inc. is a U.S. public company in medicinal chemicals & botanical products (SIC 2833), headquartered in Los Angeles, CA. It trades as NAGE on Nasdaq. Revenue was $129M in the fiscal year ending December 31, 2025, +29.9% from the year before. It reported about 117 employees. Rob Fried is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $129M 10-K, 2026-03-04 | $99.6M 10-K, 2026-03-04 | $83.6M 10-K, 2025-03-04 | $72.0M 10-K, 2024-03-06 | $67.4M 10-K, 2023-03-08 |
| Operating income | $16.3M 10-K, 2026-03-04 | $7.7M 10-K, 2026-03-04 | -$5.6M 10-K, 2025-03-04 | -$18.6M 10-K, 2024-03-06 | -$27.1M 10-K, 2023-03-08 |
| SG&A | $62.6M 10-K, 2026-03-04 | $47.8M 10-K, 2026-03-04 | $51.4M 10-K, 2025-03-04 | $56.6M 10-K, 2024-03-06 | $64.7M 10-K, 2023-03-08 |
| Net income | $17.4M 10-K, 2026-03-04 | $8.6M 10-K, 2026-03-04 | -$4.9M 10-K, 2025-03-04 | -$16.5M 10-K, 2024-03-06 | -$27.1M 10-K, 2023-03-08 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Rob Fried | Chief Executive Officer | 8-K, 2026-11-04 |
| Robert N. Fried | Chief Executive Officer | 4, 2026-07-08 |
| Ozan Pamir | Chief Financial Officer | 4, 2026-07-08 |
| Carlos Luis Lopez | SVP, General Counsel | 4, 2026-07-08 |
| Frank Jaksch Jr. | Chairman of the Board and Director | 10-K, 2026-03-04 |
| Ann Cohen | Director | 10-K, 2026-03-04 |
| Gary Ng | Director | 10-K, 2026-03-04 |
| Hamed Shahbazi | Director | 10-K, 2026-03-04 |
| Kristin Patrick | Director | 10-K, 2026-03-04 |
| Steven Rubin | Director | 10-K, 2026-03-04 |
| Wendy Yu | Director | 10-K, 2026-03-04 |
What Niagen Bioscience, Inc. does
, a California corporation and wholly-owned subsidiary of Cody (Acquisition Sub), and ChromaDex, Inc. (Merger). Subsequent to the signing of the Merger Agreement, Cody merged with and into a Delaware corporation. On June 20, 2008, Cody amended its articles of incorporation to change its name to ChromaDex Corporation. On April 25, 2016, ChromaDex Corporation became listed on the Nasdaq Capital Market (Nasdaq).
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 79.2 million (as of October 30, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $814M (as of June 30, 2025) | 10-K, March 4, 2026 |
| Reportable segments | 4 (period ending September 30, 2026) | 10-Q, November 4, 2026 |
| Latest proxy statement | Meeting June 24, 2026 (filed April 29, 2026) | DEF 14A, April 29, 2026 |
| Auditor | Crowe LLP (Costa Mesa, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 14, 2025 | Ozan Pamir Chief Financial Officer | Buy | 6,685 | $46K | Form 4, November 17, 2025 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-04
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-29
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-03-19
- Item 8.01 Other events
- 8-K filed 2026-03-04
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-26
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2025-12-22
- Item 1.01 Entry into a material definitive agreement
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-11-06
- Item 8.01 Other events
- 8-K filed 2025-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Niagen Bioscience, Inc.
- What does Niagen Bioscience, Inc. do?
- In its own words, from Item 1 of its 10-K: ", a California corporation and wholly-owned subsidiary of Cody (Acquisition Sub), and ChromaDex, Inc. (Merger). Subsequent to the signing of the Merger Agreement, Cody merged with and into a Delaware corporation. On June 20, 2008, Cody amended its articles of incorporation to change its name to ChromaDex Corporation. On April 25, 2016, ChromaDex Corporation became listed on the Nasdaq Capital Market (Nasdaq)."
- What is Niagen Bioscience, Inc.'s revenue?
- $129M for the fiscal year ending December 31, 2025, from its 10-K filed March 4, 2026.
- Is Niagen Bioscience, Inc. profitable?
- Niagen Bioscience, Inc. reported net income of $17.4M for the fiscal year ending December 31, 2025.
- How many employees does Niagen Bioscience, Inc. have?
- About 117 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Niagen Bioscience, Inc.?
- Rob Fried, Chief Executive Officer, as named in a 8-K filed November 4, 2026.
- Who is the CFO of Niagen Bioscience, Inc.?
- Ozan Pamir, Chief Financial Officer, as named in a 4 filed July 8, 2026.
- Where is Niagen Bioscience, Inc. headquartered?
- Los Angeles, CA.
- What is Niagen Bioscience, Inc.'s stock ticker?
- NAGE on Nasdaq.
- What industry is Niagen Bioscience, Inc. in?
- Medicinal Chemicals & Botanical Products, SIC code 2833.
- What is Niagen Bioscience, Inc.'s website?
- niagenbioscience.com. Investor relations: https://investors.niagenbioscience.com/overview/default.aspx.
- When does Niagen Bioscience, Inc. report earnings next?
- February 2, 2027. Source: estimate_8k_pattern.
- Is Niagen Bioscience, Inc. a public company?
- Yes. Niagen Bioscience, Inc. files with the SEC under CIK 0001386570 and trades as NAGE.
- Who audits Niagen Bioscience, Inc.?
- Crowe LLP, Costa Mesa, California, as named in its latest annual report (10-K).
- How many shares of Niagen Bioscience, Inc. are outstanding?
- 79.2 million shares as of October 30, 2026, from its 10-Q filed November 4, 2026.
- What is Niagen Bioscience, Inc.'s public float?
- $814M as of June 30, 2025, as reported on the cover of its 10-K filed March 4, 2026.
- How many business segments does Niagen Bioscience, Inc. report?
- 4 reportable segments for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
- When is Niagen Bioscience, Inc.'s annual shareholder meeting?
- June 24, 2026, per its proxy statement (DEF 14A) filed April 29, 2026.
- Have Niagen Bioscience, Inc. insiders traded stock recently?
- Since November 14, 2025, officers and directors reported 0 open-market sales and 1 purchase worth about $46K on Forms 4 and 5. The most recent: Ozan Pamir (Chief Financial Officer) bought 6,685 shares on November 14, 2025.